Home  |  Contact

UniProtKB/Swiss-Prot Q06210: Variant p.Thr15Ala

Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1
Gene: GFPT1
Variant information

Variant position:  15
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Threonine (T) to Alanine (A) at position 15 (T15A, p.Thr15Ala).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to small size and hydrophobic (A)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CMS12.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  15
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  699
The length of the canonical sequence.

Location on the sequence:   MCGIFAYLNYHVPR  T RREILETLIKGLQRLEYRGY
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         MCGIFAYLNYHVPRTRREILETLIKGLQRLEYRGY

Mouse                         MCGIFAYLNYHVPRTRREILETLIKGLQRLEYRGY

Rat                           MCGIFAYLNYHVPRTRREILETLIKGLQRLEYRGY

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Initiator methionine 1 – 1 Removed
Chain 2 – 699 Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1
Domain 2 – 305 Glutamine amidotransferase type-2
Active site 2 – 2 For GATase activity
Beta strand 3 – 15


Literature citations

Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect.
Senderek J.; Muller J.S.; Dusl M.; Strom T.M.; Guergueltcheva V.; Diepolder I.; Laval S.H.; Maxwell S.; Cossins J.; Krause S.; Muelas N.; Vilchez J.J.; Colomer J.; Mallebrera C.J.; Nascimento A.; Nafissi S.; Kariminejad A.; Nilipour Y.; Bozorgmehr B.; Najmabadi H.; Rodolico C.; Sieb J.P.; Steinlein O.K.; Schlotter B.; Schoser B.; Kirschner J.; Herrmann R.; Voit T.; Oldfors A.; Lindbergh C.; Urtizberea A.; von der Hagen M.; Hubner A.; Palace J.; Bushby K.; Straub V.; Beeson D.; Abicht A.; Lochmuller H.;
Am. J. Hum. Genet. 88:162-172(2011)
Cited for: VARIANTS CMS12 ALA-15; MET-15; VAL-43; CYS-111; THR-121; PHE-199; TYR-366; HIS-403; HIS-452; THR-509; THR-510; TRP-514 AND TRP-530;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.